Last Updated: November 16, 2026

Details for Patent: 7,982,043

« Back to Dashboard


Summary for Patent: 7,982,043
Title:Protein tyrosine kinase enzyme inhibitors
Abstract:This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
Inventor(s):Allan Wissner, Sridhar Krishna Rabindran, Hwei-Ru Tsou
Assignee: Wyeth LLC
Application Number:US12/136,357
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,982,043
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 7,982,043: Claim Scope, Enforceability, and Patent Landscape

U.S. Patent No. 7,982,043 contains a narrow method-of-treatment claim directed to administering one specifically identified quinoline derivative, or a pharmaceutically acceptable salt, to treat or inhibit breast-cancer growth in a mammal. The claim does not cover the compound as a composition of matter, other cancers, or all kinase inhibitors. Its commercial value depends on the related composition, formulation, manufacturing, and method-of-use patents in the same patent family.

What does U.S. Patent 7,982,043 claim?

Claim 1 covers the following elements:

Claim element Scope
Subject A mammal in need of treatment
Disease Breast cancer
Therapeutic objective Treating breast cancer or inhibiting its growth
Action Administering an effective amount
Active agent One specifically named quinoline compound
Chemical form The named compound or a pharmaceutically acceptable salt

The claim is an apparatus-independent method claim. It is infringed, if otherwise valid and enforceable, by carrying out the claimed administration method. It does not require a particular formulation, dosage strength, route of administration, treatment duration, disease stage, biomarker, or combination partner.

The active compound is:

(E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide.

The claim’s “selected from” language does not materially broaden the claim because only one compound is listed. The alternative covered chemical forms are the neutral compound and pharmaceutically acceptable salts.

How narrow is the breast-cancer treatment claim?

The claim is narrow in chemical identity but broad in clinical implementation.

Chemical limitations

A practicing party must administer the specifically recited molecule or a pharmaceutically acceptable salt. A structurally related analog with a different substituent, stereochemistry, linker, or heteroaryl group would generally fall outside the literal chemical limitation unless the patent’s other claims or the doctrine of equivalents applies.

The following changes could be material:

  • replacing the 2-pyridinylmethoxy substituent;
  • changing the E configuration of the butenamide;
  • altering the 3-chloro or 7-ethoxy substituents;
  • replacing the dimethylamino group;
  • changing the quinoline core;
  • administering a covalent derivative, prodrug, metabolite, or different polymorph.

Whether a salt falls within the claim depends on whether it is a pharmaceutically acceptable salt of the same active compound. The claim does not expressly identify particular counterions, such as hydrochloride, mesylate, fumarate, maleate, or sulfate.

Disease limitation

The claim is limited to breast cancer. Administration for renal-cell carcinoma, lung cancer, colorectal cancer, ovarian cancer, glioblastoma, or another cancer would not literally satisfy the disease limitation, even if the compound has anticancer activity in those diseases.

The claim does not limit breast cancer by:

  • HER2 status;
  • estrogen-receptor status;
  • progesterone-receptor status;
  • metastatic or early-stage disease;
  • adjuvant or neoadjuvant use;
  • prior exposure to HER2-directed therapy;
  • resistance status;
  • mutation profile.

That breadth increases the method claim’s potential coverage against clinical use, but it also creates validity and enablement issues if the patent specification does not support the full breadth of breast-cancer treatment.

What is the likely infringement exposure under Claim 1?

A product or clinical program has the highest exposure when all of the following conditions are present:

  1. The active ingredient is the claimed compound or a covered salt.
  2. The indication is breast cancer.
  3. The product label, clinical protocol, promotional activity, or prescribing practice supports the claimed use.
  4. The accused party administers, directs, induces, or contributes to administration.

A generic or follow-on manufacturer could face direct method-of-use risk if its labeling instructs treatment of breast cancer. A manufacturer may face induced-infringement allegations if it markets the drug with instructions that encourage physicians to perform the claimed method.

A product sold for a non-breast-cancer indication presents a different risk profile. The principal questions would be whether the label contains breast-cancer instructions, whether the manufacturer actively promotes that use, and whether substantial use of the product is for the patented method.

The claim does not require monotherapy. Combination treatment can satisfy the claim if the patented compound is administered in an effective amount for breast cancer. The claim also does not exclude prior or concurrent treatment with chemotherapy, endocrine therapy, radiation, immunotherapy, or another targeted agent.

What does “effective amount” add to the claim?

“Effective amount” is a functional limitation. The administered quantity must be sufficient to produce the claimed therapeutic result, treating breast cancer or inhibiting its growth.

The claim does not specify:

  • a minimum dose;
  • a maximum dose;
  • a plasma concentration;
  • a treatment cycle;
  • a response threshold;
  • tumor-shrinkage criteria;
  • progression-free survival;
  • overall-survival improvement.

In litigation, the specification and prosecution history would be important in determining how “effective amount” is construed. The term generally does not require a cure. Inhibition of tumor growth may be sufficient if supported by the patent’s disclosure and the facts of the accused use.

Does Claim 1 cover the compound itself?

No. Claim 1 is a method claim.

It does not, by itself, prevent a party from:

  • making the compound;
  • possessing the compound;
  • importing the compound;
  • selling the compound for a non-breast-cancer use;
  • developing a formulation;
  • conducting certain preclinical or regulatory activities.

Separate composition-of-matter, pharmaceutical-composition, formulation, process, salt, polymorph, or broader method claims would be required to create those forms of protection.

The patent may contain additional claims, but the supplied text is insufficient to attribute broader protection to Patent 7,982,043. Claim analysis should therefore distinguish the supplied claim from the patent’s complete claim set.

What related patents are likely to matter?

A commercial patent estate for this type of kinase inhibitor would normally divide into several layers:

Patent layer Typical subject matter Commercial effect
Composition of matter The active quinoline compound and analogs Primary barrier to independent generic development
Salts and solid forms Salt selection, polymorphs, hydrates, solvates Can delay substitution or complicate ANDA certification
Pharmaceutical compositions Excipients, dosage forms, stability, release profile Protects marketed product presentation
Methods of treatment Breast cancer and other tumor types Supports label-based enforcement
Combination therapy Use with endocrine, cytotoxic, or targeted therapy Extends indication-specific protection
Manufacturing Intermediates, coupling steps, purification, crystallization Increases design-around and scale-up costs
Dosing regimens Loading doses, intermittent dosing, toxicity management Can create later-expiring use protection
Formulation technology Tablets, capsules, dispersions, solid solutions Relevant to generic product design

The composition patent generally has the greatest leverage because a generic manufacturer cannot avoid it merely by changing the label. A method claim such as Claim 1 has narrower enforcement reach but can still block a breast-cancer label or create litigation risk for a product whose commercial use is concentrated in breast cancer.

When does U.S. Patent 7,982,043 lose exclusivity?

Patent expiration cannot be determined from Claim 1 alone. The controlling calculation requires the patent’s earliest effective nonprovisional filing date, priority chain, patent-term adjustment, terminal disclaimers, and any patent-term extension. U.S. patent term is generally governed by 35 U.S.C. § 154 and runs 20 years from the relevant earliest nonprovisional filing date, subject to statutory adjustments.[1]

The patent issued on July 19, 2011. Issuance date is not the expiration date. A continuation or divisional relationship can produce a patent with the same effective term as an earlier family member, while a later-filed continuation may have a different term only in limited circumstances. Terminal disclaimers can also tie the patent to another patent’s expiration date.

For a freedom-to-operate review, the relevant timeline must include:

Event Relevance
Earliest priority filing Establishes priority and supports the patent family
Earliest nonprovisional filing Central to statutory patent-term calculation
Patent issuance Starts enforceable patent rights, subject to prior publication and other rules
Patent-term adjustment May extend the nominal term
Patent-term extension Potentially available for qualifying regulatory delay
Terminal disclaimer May shorten the term
Post-grant proceedings May cancel, amend, or preserve claims
Expiration or disclaimer Ends enforceability of surviving claims

A patent’s expiration also does not eliminate later-expiring patents covering formulations, salts, polymorphs, dosing regimens, or approved methods.

What is the Orange Book status of the claimed compound?

Orange Book status cannot be inferred from the patent claim alone. The FDA Orange Book lists patents submitted by an NDA holder for an approved drug product, not every patent that claims a drug compound or its use.[2]

The key questions are:

  • whether the claimed compound has an approved NDA;
  • whether the NDA holder submitted Patent 7,982,043 to FDA;
  • whether FDA accepted the listing;
  • whether the listing covers the active ingredient, drug product, or method of use;
  • whether the patent remains listed or has been delisted;
  • whether an ANDA applicant has filed a Paragraph IV certification.

If the compound has no approved NDA, there is no Orange Book-listed product patent for that compound. Patent rights can still exist outside the Orange Book, including for preclinical development, nonapproved uses, manufacturing, and contractual licensing.

What Paragraph IV challenges could affect this patent?

An ANDA applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product.[3]

For a breast-cancer method claim, the main challenge theories would include:

  • anticipation by an earlier publication or patent;
  • obviousness based on earlier kinase inhibitors and the claimed substituent pattern;
  • inadequate written description for the specific compound;
  • lack of enablement across the claimed breast-cancer use;
  • indefiniteness in terms such as “effective amount” or “inhibiting growth”;
  • noninfringement based on a label that omits breast-cancer treatment;
  • improper patent listing if the patent does not claim the approved product or an approved method of use.

The risk of a Paragraph IV challenge is highest when the patent is listed in the Orange Book and its remaining term is commercially significant. A method patent generally creates less product-wide exposure than a composition patent because a generic applicant may attempt a section viii carve-out for an unpatented use, subject to the FDA’s labeling rules.[4]

Which companies could challenge the patent?

Potential challengers would include generic pharmaceutical companies with the manufacturing capacity to produce the active ingredient or a therapeutically equivalent product. Typical ANDA litigants in oncology products include companies such as Teva, Sandoz, Sun Pharma, Lupin, Dr. Reddy’s, Cipla, Aurobindo, Zydus, and Amneal.

No company should be treated as a confirmed challenger without a filed Paragraph IV notice, a complaint under the Hatch-Waxman Act, an FDA Orange Book record, or a public settlement or litigation docket. The patent number and supplied claim do not establish that any particular company has challenged Patent 7,982,043.

How strong is the patent estate?

The supplied claim has moderate strength as an indication-specific enforcement tool and limited strength as a standalone product barrier.

Strengths

  • It identifies the active compound precisely.
  • It covers both treatment and inhibition of breast-cancer growth.
  • It applies to any mammal, including humans.
  • It does not require a particular biomarker, dose, route, or combination.
  • It covers pharmaceutically acceptable salts.

Weaknesses

  • It does not claim the compound as such.
  • It is limited to breast cancer.
  • It may be vulnerable if the specification provides limited clinical support.
  • The single-compound selection limits chemical breadth.
  • A non-breast-cancer label may reduce inducement exposure.
  • The claim may have little residual value after expiration of composition patents or regulatory exclusivity.

Commercial strength therefore depends on the broader family. A composition patent, an Orange Book-listed method patent, a later formulation patent, and regulatory exclusivity would create materially stronger protection than Claim 1 standing alone.

What is the competitive and commercial significance?

A breast-cancer method claim is commercially meaningful when the active compound has a breast-cancer label and the indication represents a major share of expected sales. Its value declines when:

  • breast cancer is only a minor clinical program;
  • the drug has no approved product;
  • the compound is abandoned;
  • a composition patent has expired;
  • competitors can sell for nonbreast-cancer uses;
  • physicians can prescribe the product without label instructions for breast cancer;
  • later patents do not cover the marketed dosage form.

The claim does not establish revenue exposure, market share, regulatory approval, or commercial launch. Those metrics require separate FDA, company, clinical-trial, and financial records.

Key Takeaways

  • Claim 1 is a narrow method claim covering one named quinoline compound and its pharmaceutically acceptable salts.
  • The disease limitation is breast cancer; the claim does not extend to all cancers.
  • The claim does not cover the compound, formulation, manufacturing process, or non-breast-cancer use by itself.
  • No specific dose, route, schedule, biomarker, treatment line, or combination partner is required.
  • The commercial impact depends on the patent’s full claim set and related composition, formulation, process, and method patents.
  • Expiration requires review of the full priority chain, patent-term adjustment, terminal disclaimers, and any regulatory extension.
  • Orange Book listing and Paragraph IV exposure cannot be established from the claim text alone.
  • A generic manufacturer’s principal risks would involve label content, induced infringement, and any separate composition-of-matter patents.

FAQs

Does Patent 7,982,043 cover all salts of the compound?

It covers pharmaceutically acceptable salts of the specifically identified compound. The claim does not expressly enumerate each counterion, so salt status would depend on chemical identity and pharmaceutical acceptability.

Can a company sell the compound for a different cancer indication?

Claim 1, by itself, is limited to breast cancer. Separate claims, patents, labeling, promotional conduct, or related family members could create additional exposure.

Does a combination product infringe the claim?

Yes, potentially. The claim does not require monotherapy. Administration of the claimed compound with another cancer treatment can satisfy the claim if the compound is administered in an effective amount for breast cancer.

Is a generic applicant automatically blocked by this patent?

No. A method patent does not automatically block all generic manufacture or sale. The analysis depends on Orange Book listing, the proposed label, any section viii carve-out, other patents, and the applicant’s Paragraph IV position.

Can the patent be enforced after its expiration date?

No surviving claim can ordinarily be enforced after the patent term ends. Later-expiring patents covering the compound, formulation, salt, polymorph, manufacturing process, or a separate treatment regimen may continue to affect market entry.

References

  1. United States Code, 35 U.S.C. § 154. Patent term and adjustment.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
  3. United States Code, 21 U.S.C. § 355(j)(2)(A)(vii)(IV). Paragraph IV certification.
  4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Patent and exclusivity information.
  5. U.S. Patent No. 7,982,043. (2011). United States Patent and Trademark Office.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,982,043

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,982,043

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2005028443 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.